EMA Opinion under re-examination: Yartemlea (narsoplimab) — Omeros Ireland Limited

View source ↗

Summary

EMA opinion under re-examination for Yartemlea (narsoplimab) by Omeros Ireland Limited in therapeutic areas including Thrombotic Microangiopathies and Hematopoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Thrombotic Microangiopathy

Drugs mentioned

• YARTEMLEA (narsoplimab)

Snippet

Status: Opinion under re-examination. Therapeutic area: Thrombotic Microangiopathies;Hematopoietic Stem Cell Transplantation. MAH: Omeros Ireland Limited. Decision date: 25/06/2026